Simplify Logo

Full-Time

Lead – Trial Master File

Posted on 6/27/2024

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

201-500 employees

Develops treatments for neurodegenerative diseases

Biotechnology
Healthcare

Senior, Expert

Remote in USA

Must reside and work within the United States in a state where Amylyx currently does business.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Management
Requirements
  • Bachelor's Degree with a minimum of 6 years of experience organizing and coordinating Trial Master Files for clinical trials
  • Experience leading projects and resources including employees, consultants and vendors.
  • High level of competency with Veeva Vault eTMF and knowledge of the TMF Reference Model.
  • Excellent organizational and problem-solving skills, able to work independently in a fast-paced environment.
  • Efficient and effective time management skills with ability to successfully manage competing priorities.
  • Strong attention to detail.
  • Familiarity with US FDA, ICH/GCP, and European Regulatory Authority requirements as applicable to a study (or the countries where a study is conducted). GCP inspection experience preferred.
Responsibilities
  • Provide leadership for all eTMF process, including but not limited to: procedural documents such as SOPs, Work Instructions or User Guides; TMF Management Plans and associated indexes; TMF migrations; Change Controls, Deviations and CAPAs.
  • Establish, follow and oversee processes and procedures to support TMF set up, maintenance, and archiving for all Amylyx clinical studies.
  • Oversee and facilitate the access management process, by ensuring appropriate internal and external access, by monitoring user access and adding new team members or deactivating users no longer requiring access.
  • Serve as TMF Subject Matter Expert for the clinical study team and supporting cross-functional departments to ensure high quality documentation. Collaborate with cross functional study team to set up TMF structure.
  • Manage TMF health and report on study-specific metrics according to TMF plan
  • Work with internal and external TMF users to ensure resolution for quality issues
  • Develop and provide training on Veeva eTMF to internal and external TMF users to ensure.
  • Participate in audits and inspection readiness activities
  • Identify areas for process improvements and work with stakeholders to implement solutions.
  • Lead migrations of TMF content to Veeva Vault, if needed, working with the Clinical Leadership team to define resourcing and efforts required to complete TMF migrations
  • Oversee Document Specialists and/or other clinical roles allocated to TMF activities.
  • Ensure that study teams classify and index TMF content and metadata according to department standards, Good Documentation Practices, and Good Clinical Practice.
Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

View

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials to assess its effectiveness. The CENTAUR ALS trial showed promising results for ALS patients, using a randomized, double-blind, placebo-controlled design to ensure reliable outcomes. They are also conducting the PEGASUS trial to evaluate AMX0035's safety and effectiveness in Alzheimer's patients. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes.

Company Stage

IPO

Total Funding

$548.9M

Headquarters

Cambridge, Massachusetts

Founded

2013

Growth & Insights
Headcount

6 month growth

-27%

1 year growth

-20%

2 year growth

23%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful acquisition of Phase 3-ready avexitide from Eiger could diversify Amylyx's pipeline and open new revenue streams.
  • Interim data from the Phase 2 HELIOS trial shows promising results for AMX0035 in treating Wolfram syndrome, indicating potential for broader applications.
  • The appointment of experienced professionals like Dr. Bernhardt Zeiher to the Board of Directors strengthens the company's leadership and strategic direction.

What critics are saying

  • The failure of the Phase III PHOENIX trial and subsequent market withdrawal of Relyvrio raises concerns about the efficacy of Amylyx's treatments.
  • A significant workforce reduction by 70% under a restructuring plan could impact company morale and operational efficiency.

What makes Amylyx Pharmaceuticals unique

  • Amylyx Pharmaceuticals focuses on neurodegenerative diseases like ALS and Alzheimer's, setting it apart from competitors with broader therapeutic areas.
  • The company's flagship product, AMX0035, has shown significant treatment benefits in rigorous clinical trials, including the CENTAUR ALS trial, which is a strong validation of its efficacy.
  • Amylyx's commitment to community engagement and awareness campaigns, such as ALS Awareness Month, enhances its brand and builds a supportive community around its cause.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE